J.P. Morgan maintains Hold Rating on Johnson & Johnson, citing growth potential and challenges

J.P. Morgan maintained their Hold Rating on Johnson & Johnson (JNJ) with a price target of $185. Analyst Chris Schott cited over 5% top-line growth potential, driven by innovative medicine and meditech. Challenges include biosimilar competition impacting Stelara sales and ongoing talc litigation. Pharmaceutical portfolio forecasted to remain flat, with notable declines in drugs like Stelara.

Schott remains cautiously optimistic about Johnson & Johnson (JNJ) despite challenges. While JNJ holds investment potential, certain AI stocks offer greater upside with less downside risk. An undervalued AI stock that benefits from Trump-era tariffs and onshoring trend is highlighted in a free report.

For more insights on the best and worst Dow stocks for the next 12 months and 10 unstoppable stocks that could double your money, visit the provided links. No disclosures mentioned in the article.

Read more at Yahoo Finance: J.P. Morgan Maintained Their Hold Rating on Johnson & Johnson (JNJ)